About the Authors
- Farshid Dayyani
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Nila U. Parikh
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Andreas S. Varkaris
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Jian H. Song
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Shhyam Moorthy
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Tanushree Chatterji
-
Affiliations Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Program in Cancer Metastasis, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America
- Sankar N. Maity
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Adam R. Wolfe
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Joan M. Carboni
-
Affiliation Department of Pharmaceutical Candidate Organization, Bristol-Myers Squibb Company, Princeton, New Jersey, United States of America
- Marco M. Gottardis
-
Affiliation Department of Pharmaceutical Candidate Organization, Bristol-Myers Squibb Company, Princeton, New Jersey, United States of America
- Christopher J. Logothetis
-
Affiliation Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
- Gary E. Gallick
-
* E-mail: ggallick@mdanderson.org
Affiliations Department of Genitourinary Medical Oncology and David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Program in Cancer Metastasis, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America
Competing Interests
The authors have read the journal's policy and have the following conflicts. They declare that J.C. and M.G. are employed by Bristol-Myers Squibb. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: FD GEG CJL SNM. Performed the experiments: FD NUP AV JHS SM TC ARW. Analyzed the data: FD GEG AV JHS CJL. Contributed reagents/materials/analysis tools: JMC MMG. Wrote the paper: FD GEG.